Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study

2016; Elsevier BV; Volume: 2; Issue: 1 Linguagem: Inglês

10.1016/s2468-1253(16)30118-2

ISSN

2468-1253

Autores

Caryn S. Ross-Innes, Hamza Chettouh, Achilleas Achilleos, Núria Galeano-Dalmau, Irene Debiram‐Beecham, Shona MacRae, Petros Fessas, Elaine Walker, Sibu Varghese, Theodore Evan, Pierre Lao-Sirieix, Maria O’Donovan, Shalini Malhotra, Marco Novelli, Babett Disep, P Kaye, Laurence Lovat, Rehan Haidry, S M Griffin, Krish Ragunath, Pradeep Bhandari, Adam Haycock, Danielle Morris, Stephen Attwood, Anjan Dhar, Colin Rees, Matt Rutter, Richard Ostler, Benoit Aigret, Peter Sasieni, Rebecca C. Fitzgerald,

Tópico(s)

Gastric Cancer Management and Outcomes

Resumo

Barrett's oesophagus predisposes to adenocarcinoma. However, most patients with Barrett's oesophagus will not progress and endoscopic surveillance is invasive, expensive, and fraught by issues of sampling bias and the subjective assessment of dysplasia. We investigated whether a non-endoscopic device, the Cytosponge, could be coupled with clinical and molecular biomarkers to identify a group of patients with low risk of progression suitable for non-endoscopic follow-up.

Referência(s)